Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis
2020; The Journal of Rheumatology Publishing Company Limited; Volume: 47; Issue: 8 Linguagem: Inglês
10.3899/jrheum.200507
ISSN1499-2752
AutoresEnnio Giulio Favalli, Elena Agape, Roberto Caporali,
Tópico(s)Autoimmune and Inflammatory Disorders Research
ResumoTo the Editor: The outbreak of COVID-19 in December 2019 in China has very quickly become a global health emergency, with almost 2 million infected patients worldwide1. Along with the spread of the pandemic, there has been growing concern about the management of fragile patients with rheumatic conditions. There are still very few data available on this aspect. In particular, subjects affected by connective tissue diseases (CTD) are known to have an increased infectious risk compared to the healthy population because of a general impairment of the immune system intrinsic to the autoimmune disease itself, the iatrogenic effect linked to the use of immunosuppressive drugs, and the high number of comorbidities that often complicate the clinical picture2,3. On the other hand, the progressive increase in the knowledge about the pathogenesis of the infection is paving the way for the use of certain drugs common in rheumatology to also treat COVID-194. As rheumatologists operating in one of the major epicenters … Address correspondence to Dr. E.G. Favalli, Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Via Gaetano Pini 9, 20122 Milan, Italy. E-mail address: enniofavalli{at}me.com
Referência(s)